$\square$ 

## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See
Instruction 1(b).

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APP	ROVAL
OMB Number:	3235-0287

Estimated average burden	
hours per response:	0.5

1. Name and Address of Reporting Person <sup>*</sup> GORMAN KEVIN CHARLES			2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
			NBIX ]	X	Director	10% Owner		
(Last) (First) (Middle)		(Middle)		x	Officer (give title below)	Other (specify below)		
NEUROCRINE BIOSCIENCES, INC.			3. Date of Earliest Transaction (Month/Day/Year) 02/28/2011	President and CEO				
12780 EL CAMINO REAL								
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applica Line)				
(Street)	СА	92130		X	Form filed by One Repor	ting Person		
SAN DIEGO CA 92150		92130			Form filed by More than One Reporting			
(City)	(State)	(Zip)			Person			

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		Securities Beneficially	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)
Common Stock	02/28/2011		<b>S</b> <sup>(1)</sup>		15,400	D	<b>\$6.8269</b> <sup>(2)</sup>	177,202	<b>D</b> <sup>(3)</sup>	

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

				1		-				1		-			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Expirat Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) Date		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v			Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

#### Explanation of Responses:

1. Sale of 15,400 shares of common stock issued upon vesting of 41,667 restricted stock units on February 27, 2011 to cover payroll and withholding taxes, with the balance of the shares (26,267) maintained by the Reporting Person; the sale was affected by a broker pursuant to instructions set forth in a Rule 10b5-1 plan adopted by the Reporting Person and delivered to the broker on May 26, 2009.

2. Represents a weighted average sales price per share. The prices actually received ranged from \$6.58 to \$7.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. 158,540 non-derivative securities are held directly by Reporting Person; 14,662 non-derivative securities are held indirectly by the KCG Limited Liability Company.

### <u>Margaret E. Valeur-Jensen, By</u> <u>Power of Attorney</u> <u>03/01/2011</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Data